© 1995 by Oxford University Press
Journal of the National Cancer Institute, Vol. 87, No. 14, 1067-1071,
July 19, 1995
© 1995 Oxford University Press
Postmenopausal Hormone Use and Risk of Large-Bowel Cancer
Department of Human Oncology, University of Wisconsin Medical School, and University of Wisconsin Comprehensive Cancer Center Madison.
Department of Biostatistics, University of Wisconsin Medical School, and University of Wisconsin Comprehensive Cancer Center Madison
*Correspondence to: Polly A. Newcomb, Ph.D., University of Wisconsin—Madison Comprehensive Cancer Center, 1300 University Ave. #4780, Madison WI 53706.
Background: The epidemiology of large-bowel cancer suggests a role for endocrine factors in its development. Although analytic studies have not consistently provided evidence for an association between reproductive history and large-bowel cancer, some relatively small studies have observed a reduced risk among women using postmenopausal hormone replacement therapy (HRT). Purpose: This study was planned to evaluate more precisely the relationship between HRT and the risk of colon and rectal cancers. Methods: Female residents of Wisconsin aged 30–74 years with a diagnosis of colon or rectal cancer within 2 years were identified through a statewide tumor registry. Control subjects were randomly selected from lists of licensed drivers if the case subjects were less than 65 years old and from lists of Medicare beneficiaries if they were 65–74 years old. Information on postmenopausal hormone replacement use, medical history, and family history was obtained in telephone interviews. After premenopausal women were excluded, 694 case subjects and 1622 control subjects remained for analysis. The odds ratios and 95% confidence intervals (CIs) obtained from conditional logistic regression models were used to estimate relative risks (RRs). All RRs were adjusted for age, family history of large-bowel cancer, use of screening sigmoidoscopy, and recent alcohol consumption. Results: Compared with postmenopausal women who never used HRT, recent users had an RR of 0.54 (95% CI = 0.36–0.81) for colon cancer and an RR of 0.91 (95% CI = 0.54–1.55) for rectal cancer. This inverse association was observed among users of both estrogen only and combined estrogen and progestin preparations. Decreasing time since last use was inversely associated with colon cancer risk (P for trend <.001). The effect of HRT appeared to be stronger among women at lower absolute risk of colon cancer, particularly among women with lean body mass. Conclusions: Use of HRT was associated with a statistically significant reduced risk of colon cancer. In contrast, no statistically significant relationship was observed for rectal cancer. Given the widespread use of postmenopausal hormones and the morbidity and mortality from adenocarcinoma of the bowel in women, these findings may have potentially important public health implications. [J Natl Cancer Inst 87:1067–1071, 1995]
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  V. M. Chia, P. A. Newcomb, J. W. Lampe, E. White, M. T. Mandelson, A. McTiernan, and J. D. Potter Leptin Concentrations, Leptin Receptor Polymorphisms, and Colorectal Adenoma Risk Cancer Epidemiol. Biomarkers Prev., December 1, 2007; 16(12): 2697 - 2703. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. A. Newcomb, Y. Zheng, V. M. Chia, L. M. Morimoto, V. P. Doria-Rose, A. Templeton, S. N. Thibodeau, and J. D. Potter Estrogen Plus Progestin Use, Microsatellite Instability, and the Risk of Colorectal Cancer in Women Cancer Res., August 1, 2007; 67(15): 7534 - 7539. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. A. Wolf, P. D. Terry, J. D. Potter, and R. M. Bostick Do Factors Related to Endogenous and Exogenous Estrogens Modify the Relationship between Obesity and Risk of Colorectal Adenomas in Women? Cancer Epidemiol. Biomarkers Prev., April 1, 2007; 16(4): 676 - 683. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Lin, S. M. Zhang, N. R. Cook, J. E. Manson, J. E. Buring, and I-M. Lee Oral Contraceptives, Reproductive Factors, and Risk of Colorectal Cancer among Women in a Prospective Cohort Study Am. J. Epidemiol., April 1, 2007; 165(7): 794 - 801. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Chan, J. A. Meyerhardt, A. T. Chan, E. L. Giovannucci, G. A. Colditz, and C. S. Fuchs Hormone Replacement Therapy and Survival After Colorectal Cancer Diagnosis J. Clin. Oncol., December 20, 2006; 24(36): 5680 - 5686. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Cotterchio, B. A. Boucher, M. Manno, S. Gallinger, A. Okey, and P. Harper Dietary Phytoestrogen Intake Is Associated with Reduced Colorectal Cancer Risk J. Nutr., December 1, 2006; 136(12): 3046 - 3053. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. B. Nichols, A. Trentham-Dietz, J. M. Hampton, and P. A. Newcomb Oral Contraceptive Use, Reproductive Factors, and Colorectal Cancer Risk: Findings from Wisconsin Cancer Epidemiol. Biomarkers Prev., May 1, 2005; 14(5): 1212 - 1218. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A Bardin, N Boulle, G Lazennec, F Vignon, and P Pujol Loss of ER{beta} expression as a common step in estrogen-dependent tumor progression Endocr. Relat. Cancer, September 1, 2004; 11(3): 537 - 551. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. T. Chlebowski, J. Wactawski-Wende, C. Ritenbaugh, F. A. Hubbell, J. Ascensao, R. J. Rodabough, C. A. Rosenberg, V. M. Taylor, R. Harris, C. Chen, et al. Estrogen plus Progestin and Colorectal Cancer in Postmenopausal Women N. Engl. J. Med., March 4, 2004; 350(10): 991 - 1004. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. D. Holmes, M. N. Pollak, and S. E. Hankinson Lifestyle Correlates of Plasma Insulin-like Growth Factor I and Insulin-like Growth Factor Binding Protein 3 Concentrations Cancer Epidemiol. Biomarkers Prev., September 1, 2002; 11(9): 862 - 867. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P D Terry, A B Miller, and T E Rohan Obesity and colorectal cancer risk in women Gut, August 1, 2002; 51(2): 191 - 194. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Woodson, E. Lanza, J. A. Tangrea, P. S. Albert, M. Slattery, J. Pinsky, B. Caan, E. Paskett, F. Iber, J. W. Kikendall, et al. Hormone Replacement Therapy and Colorectal Adenoma Recurrence Among Women in the Polyp Prevention Trial J Natl Cancer Inst, December 5, 2001; 93(23): 1799 - 1805. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Giovannucci Insulin, Insulin-Like Growth Factors and Colon Cancer: A Review of the Evidence J. Nutr., November 1, 2001; 131(11): 3109S - 3120. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. C. Gallagher, O. Geling, J. FitzGibbons, J. Aforismo, and F. Comite Are Women Being Counseled about Estrogen Replacement Therapy? Med Care Res Rev, November 1, 2000; 57(3_suppl): 72 - 92. [Abstract] [PDF]
|
|
|
|
|
|
N. Prihartono, J. R. Palmer, C. Louik, S. Shapiro, and L. Rosenberg A Case-Control Study of Use of Postmenopausal Female Hormone Supplements in Relation to the Risk of Large Bowel Cancer Cancer Epidemiol. Biomarkers Prev., April 1, 2000; 9(4): 443 - 447. [Abstract] [Full Text]
|
|
|
|
|
|
E. F. Foley, A. A. Jazaeri, M. A. Shupnik, O. Jazaeri, and L. W. Rice Selective Loss of Estrogen Receptor {beta} in Malignant Human Colon Cancer Res., January 1, 2000; 60(2): 245 - 248. [Abstract] [Full Text]
|
|
|
|
|
|
J. D. Potter Colorectal Cancer: Molecules and Populations J Natl Cancer Inst, June 2, 1999; 91(11): 916 - 932. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Fowble, A. Hanlon, G. Freedman, A. Patchefsky, H. Kessler, N. Nicolaou, J. Hoffman, E. Sigurdson, M. Boraas, and L. Goldstein Postmenopausal Hormone Replacement Therapy: Effect on Diagnosis and Outcome in Early-Stage Invasive Breast Cancer Treated With Conservative Surgery and Radiation J. Clin. Oncol., June 1, 1999; 17(6): 1680 - 1680. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. Santen and G. R. Petroni Relative Versus Attributable Risk of Breast Cancer from Estrogen Replacement Therapy J. Clin. Endocrinol. Metab., June 1, 1999; 84(6): 1875 - 1881. [Full Text]
|
|
|
|
|
|
M. A. English, K. F. Kane, N. Cruickshank, M. J. S. Langman, P. M. Stewart, and M. Hewison Loss of Estrogen Inactivation in Colonic Cancer J. Clin. Endocrinol. Metab., June 1, 1999; 84(6): 2080 - 2085. [Abstract] [Full Text]
|
|
|
|
 |
|
 K. Nanda, L. A. Bastian, V. Hasselblad, and D. L. Simel HORMONE REPLACEMENT THERAPY AND THE RISK OF COLORECTAL CANCER: A META-ANALYSIS Obstet. Gynecol., May 1, 1999; 93(5): 880 - 888. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Baron, G. B. Holzman, and J. Schulkin Attitudes of Obstetricians and Gynecologists toward Hormone Replacement Therapy Med Decis Making, October 1, 1998; 18(4): 406 - 411. [Abstract] [PDF]
|
|
|
|
|
|
M LANGMAN and P BOYLE Chemoprevention of colorectal cancer Gut, October 1, 1998; 43(4): 578 - 585. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Barrett-Connor Fortnightly review: Hormone replacement therapy BMJ, August 15, 1998; 317(7156): 457 - 461. [Full Text]
|
|
|
|
|
|
E. Enmark, M. Pelto-Huikko, K. Grandien, S. Lagercrantz, J. Lagercrantz, G. Fried, M. Nordenskjold, and J.-A. Gustafsson Human Estrogen Receptor {beta}-Gene Structure, Chromosomal Localization, and Expression Pattern J. Clin. Endocrinol. Metab., December 1, 1997; 82(12): 4258 - 4265. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. A. Johnson, S. A. Prindiville, G. Morgan, D. F. Roychowdhury, A.A. van Bodegraven, J. Lourens, J.W. Sindram, H. J. Kaufmann, M. Schuler, E. Giovannucci, et al. Aspirin and the Risk of Colorectal Cancer in Women N. Engl. J. Med., January 11, 1996; 334(2): 119 - 122. [Full Text]
|
|